GANX vs. AADI, CLNN, BLRX, OCUP, ELDN, HCWB, RMTI, CELU, RPHM, and XLO
Should you be buying Gain Therapeutics stock or one of its competitors? The main competitors of Gain Therapeutics include Aadi Bioscience (AADI), Clene (CLNN), BioLineRx (BLRX), Ocuphire Pharma (OCUP), Eledon Pharmaceuticals (ELDN), HCW Biologics (HCWB), Rockwell Medical (RMTI), Celularity (CELU), Reneo Pharmaceuticals (RPHM), and Xilio Therapeutics (XLO). These companies are all part of the "pharmaceutical preparations" industry.
Aadi Bioscience (NASDAQ:AADI) and Gain Therapeutics (NASDAQ:GANX) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, media sentiment, earnings, profitability, analyst recommendations, risk, community ranking, institutional ownership and dividends.
52.1% of Aadi Bioscience shares are owned by institutional investors. Comparatively, 12.0% of Gain Therapeutics shares are owned by institutional investors. 35.8% of Aadi Bioscience shares are owned by insiders. Comparatively, 11.0% of Gain Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Gain Therapeutics has a net margin of 0.00% compared to Gain Therapeutics' net margin of -288.72%. Gain Therapeutics' return on equity of -61.83% beat Aadi Bioscience's return on equity.
Gain Therapeutics received 12 more outperform votes than Aadi Bioscience when rated by MarketBeat users. Likewise, 62.16% of users gave Gain Therapeutics an outperform vote while only 47.83% of users gave Aadi Bioscience an outperform vote.
Aadi Bioscience has a beta of 0.64, indicating that its share price is 36% less volatile than the S&P 500. Comparatively, Gain Therapeutics has a beta of 0.52, indicating that its share price is 48% less volatile than the S&P 500.
In the previous week, Gain Therapeutics had 2 more articles in the media than Aadi Bioscience. MarketBeat recorded 13 mentions for Gain Therapeutics and 11 mentions for Aadi Bioscience. Aadi Bioscience's average media sentiment score of 1.28 beat Gain Therapeutics' score of 0.15 indicating that Gain Therapeutics is being referred to more favorably in the news media.
Gain Therapeutics has lower revenue, but higher earnings than Aadi Bioscience. Gain Therapeutics is trading at a lower price-to-earnings ratio than Aadi Bioscience, indicating that it is currently the more affordable of the two stocks.
Aadi Bioscience presently has a consensus target price of $20.50, suggesting a potential upside of 973.30%. Gain Therapeutics has a consensus target price of $8.50, suggesting a potential upside of 223.19%. Given Gain Therapeutics' higher possible upside, equities research analysts clearly believe Aadi Bioscience is more favorable than Gain Therapeutics.
Summary
Gain Therapeutics beats Aadi Bioscience on 10 of the 18 factors compared between the two stocks.
Get Gain Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for GANX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding GANX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Gain Therapeutics Competitors List
Related Companies and Tools
